<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00481091</url>
  </required_header>
  <id_info>
    <org_study_id>M06-873</org_study_id>
    <secondary_id>2007-002143-25</secondary_id>
    <nct_id>NCT00481091</nct_id>
  </id_info>
  <brief_title>A Phase 1/2a Study of ABT-263 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of
      ABT-263 under two different dosing schedules with the objective of defining the dose limiting
      toxicity and maximum tolerated dose. The Phase 2a portion of the study will evaluate ABT-263
      at the defined recommended Phase 2 dose to obtain additional safety information and a
      preliminary assessment of efficacy. The Extension Study portion will allow active subjects to
      continue to receive ABT-263 for up to 9 years after the last subject transitions with less
      frequent study evaluations.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 25, 2007</start_date>
  <completion_date type="Anticipated">July 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 8, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects with Adverse Events in the in the Dose Escalation Phase (Phase 1)</measure>
    <time_frame>From first dose of study drug to 30 days after the last dose of study drug (up to approximately 13 years)</time_frame>
    <description>Treatment emergent adverse events defined as any adverse event from the time of study drug administration until 30 days after the last dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Potentially Clinically Significant (PCS) Hematology Values in the Dose Escalation Phase (Phase 1)</measure>
    <time_frame>Up to approximately 13 years</time_frame>
    <description>Blood samples for clinical laboratory tests will be collected throughout the study for clinical laboratory tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with PCS Clinical Chemistry Values in the Dose Escalation Phase (Phase 1)</measure>
    <time_frame>Up to approximately 13 years</time_frame>
    <description>Blood samples for clinical laboratory tests will be collected throughout the study for clinical laboratory tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with PCS Vital Signs Values in the Dose Escalation Phase (Phase 1)</measure>
    <time_frame>Up to approximately 13 years</time_frame>
    <description>Vital signs will be collected throughout the study for clinical laboratory tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Dose Limiting Toxicity (DLT) in the Dose Escalation Phase (Phase 1)</measure>
    <time_frame>Cycle 1 (14 days on therapy and 7 days off therapy OR 21 days continuous dosing)</time_frame>
    <description>DLTs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) in the Dose Escalation Phase (Phase 1)</measure>
    <time_frame>Cycle 1 (14 days on therapy and 7 days off therapy OR 21 days continuous dosing)</time_frame>
    <description>The MTD will be determined by using available clinical data during dose escalation in phase 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RPTD) Determined in the Dose Escalation Phase (Phase 1)</measure>
    <time_frame>Cycle 1 (14 days on therapy and 7 days off therapy OR 21 days continuous dosing)</time_frame>
    <description>The RPTD will be determined based on observed dose-limiting toxicities (DLTs) and/or determination of the maximum tolerated dose (MTD) in phase 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentrations of navitoclax on Cycle 1, Day 1 in the Dose Escalation Phase (Phase 1)</measure>
    <time_frame>Day 1</time_frame>
    <description>Plasma concentrations of navitoclax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentrations of navitoclax on Cycle 1, Day 14 in the Dose Escalation Phase (Phase 1)</measure>
    <time_frame>Day 14</time_frame>
    <description>Plasma concentrations of navitoclax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of navitoclax on Cycle 1, Day 1 in the Dose Escalation Phase (Phase 1)</measure>
    <time_frame>Day 1</time_frame>
    <description>Cmax of navitoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of navitoclax on Cycle 1, Day 14 in the Dose Escalation Phase (Phase 1)</measure>
    <time_frame>Day 14</time_frame>
    <description>Cmax of navitoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve over time from 0 to 24 hours (AUC0-24) of navitoclax on Cycle 1, Day 1 in the Dose Escalation Phase (Phase 1)</measure>
    <time_frame>Day 1</time_frame>
    <description>AUC0-24 of navitoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24 of navitoclax on Cycle 1, Day 14 in the Dose Escalation Phase (Phase 1)</measure>
    <time_frame>Day 14</time_frame>
    <description>AUC0-24 of navitoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax) of navitoclax on Cycle 1, Day 1 in the Dose Escalation Phase (Phase 1)</measure>
    <time_frame>Day 1</time_frame>
    <description>Cmax of navitoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of navitoclax on Cycle 1, Day 14 in the Dose Escalation Phase (Phase 1)</measure>
    <time_frame>Day 14</time_frame>
    <description>Cmax of navitoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects with Adverse Events in the Recommended Phase 2 Dose Phase (Phase 2)</measure>
    <time_frame>From first dose of study drug to 30 days after the last dose of study drug (up to approximately 13 years)</time_frame>
    <description>Treatment emergent adverse events defined as any adverse event from the time of study drug administration until 30 days after the last dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with PCS Hematology Values in the Recommended Phase 2 (RPTD) Phase (Phase 2)</measure>
    <time_frame>Up to approximately 13 years</time_frame>
    <description>Blood samples for clinical laboratory tests will be collected throughout the study for clinical laboratory tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with PCS Clinical Chemistry Values in the Recommended Phase 2 Dose (RPTD) Phase (Phase 2)</measure>
    <time_frame>Up to approximately 13 years</time_frame>
    <description>Blood samples for clinical laboratory tests will be collected throughout the study for clinical laboratory tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with PCS Vital Signs Values in the Recommended Phase 2 Dose (RPTD) Phase (Phase 2)</measure>
    <time_frame>Up to approximately 13 years</time_frame>
    <description>Vital signs will be collected throughout the study for clinical laboratory tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentrations of navitoclax on Cycle 1, Day 15 in the Recommended Phase 2 Dose (RPTD) Phase (Phase 2)</measure>
    <time_frame>Day 15</time_frame>
    <description>Plasma concentrations of navitoclax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of navitoclax on Cycle 1, Day 15 in the Recommended Phase 2 Dose (RPTD) Phase (Phase 2)</measure>
    <time_frame>Day 15</time_frame>
    <description>Cmax of navitoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24 of navitoclax on Cycle 1, Day 15 in the Recommended Phase 2 Dose (RPTD) Phase (Phase 2)</measure>
    <time_frame>Day 15</time_frame>
    <description>AUC0-24 of navitoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of navitoclax on Cycle 1, Day 15 in the Recommended Phase 2 Dose (RPTD) Phase (Phase 2)</measure>
    <time_frame>Day 15</time_frame>
    <description>Cmax of navitoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects with Adverse Events in the Extension Study</measure>
    <time_frame>From first dose of study drug to 30 days after the last dose of study drug (up to approximately 13 years)</time_frame>
    <description>Treatment emergent adverse events defined as any adverse event from the time of study drug administration until 30 days after the last dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with PCS Hematology Values in the Extension Study</measure>
    <time_frame>Up to approximately 13 years</time_frame>
    <description>Blood samples for clinical laboratory tests will be collected throughout the study for clinical laboratory tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with PCS Clinical Chemistry Values in the Extension Study</measure>
    <time_frame>Up to approximately 13 years</time_frame>
    <description>Blood samples for clinical laboratory tests will be collected throughout the study for clinical laboratory tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with PCS Vital Signs Values in the Extension Study</measure>
    <time_frame>Up to approximately 13 years</time_frame>
    <description>Vital signs will be collected throughout the study for clinical laboratory tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to approximately 13 years</time_frame>
    <description>PFS defined as the time from the date the participant started study drug to the date the participant experiences an event of disease progression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 13 years</time_frame>
    <description>OS defined as the time from the date the participant started study drug to the date the participant's death.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm NA, Group is Applicable</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group/Cohort Number or Label is numerical and sequential starting with dose level 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-263</intervention_name>
    <description>Phase 1 dosing under two different schedules: 14 days on drug, 7 days or (14/21) or continuous dosing.
Phase 2a dosing at the recommended phase 2a dose and schedule</description>
    <arm_group_label>Arm NA, Group is Applicable</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsed or refractory Chronic Lymphocytic Leukemia and require treatment in opinion
             of investigator

          -  Eastern Cooperative Oncology Group (ECOG) &lt;= 1

          -  Adequate bone marrow independent of growth factor support, renal and hepatic function
             per defined laboratory criteria

        Exclusion Criteria:

          -  History or clinically suspicious for cancer-related Central Nervous System disease

          -  Receipt of allogenic or autologous stem cell transplant

          -  Recent history (within 1 year of first dose) of underlying, predisposing condition of
             bleeding or currently exhibits signs of bleeding

          -  Active peptic ulcer disease or other potentially hemorrhagic esophagitis/gastritis

          -  Active immune thrombocytopenic purpura or history of being refractory to platelet
             transfusions (within 1 year of first dose)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ucsd /Id# 5566</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute /ID# 5547</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Nebraska Med Ctr /ID# 12261</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital /ID# 12267</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center /ID# 5575</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties /ID# 26428</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Ctr /ID# 6583</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital /ID# 5576</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Koln /ID# 5924</name>
      <address>
        <city>KÃ¶ln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary /ID# 15081</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 30, 2007</study_first_submitted>
  <study_first_submitted_qc>May 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2007</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Navitoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

